{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:13:49Z","timestamp":1779923629643,"version":"3.53.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":76,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.nefroe.2021.11.011","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:28:13Z","timestamp":1640190493000},"page":"578-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sofosbuvir-based regimens for HCV in stage 4\u2013stage 5 chronic kidney disease. A systematic review with meta-analysis"],"prefix":"10.1016","volume":"41","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cerutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Ridruejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2021.11.011_bib0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"8","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group","year":"2018","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0240","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.kint.2018.11.038","article-title":"Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients","volume":"95","author":"Jadoul","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0245","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clinre.2018.10.009","article-title":"Hepatitis C virus and mortality among patients on dialysis: a systematic review and meta-analysis","volume":"43","author":"Fabrizi","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0250","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.12998\/wjcc.v7.i11.1270","article-title":"Anti-hepatitis C virus therapy in chronic kidney disease patients improve long-term renal and patient survivals","volume":"7","author":"Chen","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0255","series-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C","author":"AASLD-IDSA HCV Guidance Panel","year":"2019"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0260","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0265","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0197-2456(85)90103-5","article-title":"The retrieval of randomised clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods","volume":"6","author":"Poynard","year":"1985","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0270","series-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der Simonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0280","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1002\/sim.1091","article-title":"Approaches to heterogeneity in meta-analysis","volume":"20","author":"Petitti","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0285","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistencies in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0290","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, and efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0295","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/23744235.2015.1078908","article-title":"Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency","volume":"47","author":"Hundemer","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0300","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12799","article-title":"DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting","volume":"29","author":"Beinhardt","year":"2016","journal-title":"Transplant Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0305","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofobuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0310","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir on hepatitis C genotype 1 \u2013 patients with end-stage renal disease on haemodialysis or GFR <30ml\/min","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0315","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full-dose sofosbuvir-based regimen given daily in haemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0320","first-page":"23","article-title":"Sosfobuvir use in the setting of end-stage renal disease: a single center experience","volume":"5","author":"Aggarwal","year":"2017","journal-title":"J Clin Transplant Hepatol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0325","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12664-017-0735-7","article-title":"Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis","volume":"36","author":"Choudhary","year":"2017","journal-title":"Ind J Gastroenterol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0330","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2147\/TCRM.S133983","article-title":"Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance haemodialysis","volume":"13","author":"Sperl","year":"2017","journal-title":"Ther Clin Risk Man"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0335","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/hep4.1035","article-title":"Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction","volume":"1","author":"Cox-North","year":"2017","journal-title":"Hepatol Comm"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0340","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MCG.0000000000000640","article-title":"Use of sofosbuvir-based treatment of chronic hepatitis C in liver transplant recipients on haemodialysis","volume":"51","author":"Saab","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0345","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/ndt\/gfw348","article-title":"Sofosbuvir-based antiviral therapy in hepatitis C virus paatients with severe renal failure","volume":"32","author":"Dumortier","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0350","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/liv.13863","article-title":"Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease","volume":"38","author":"Kumar","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0355","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12983","article-title":"Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency","volume":"25","author":"Singh","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0360","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12664-018-0833-1","article-title":"Preliminary experience with sosfosbuvir-based treatment regimens for patients dependent on haemodialysis","volume":"37","author":"Mehta","year":"2018","journal-title":"Ind J Gastroenterol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0365","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/nep.13050","article-title":"Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: a retrospective study","volume":"23","author":"Akhil","year":"2018","journal-title":"Nephrology"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0370","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.14429","article-title":"Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis","volume":"47","author":"He","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0375","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s10620-018-4979-6","article-title":"Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal diseases","volume":"63","author":"Taneja","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0380","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/apt.14799","article-title":"Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir+dasabuvir in patients with chronic kidney disease: an ERCHIVES study","volume":"48","author":"Butt","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0385","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/0391398818763478","article-title":"\u2018Real-life\u2019experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease","volume":"41","author":"Garcia-Agudo","year":"2018","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0390","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/hdi.12604","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection in end stage renal patients: a retrospective observational study","volume":"22","author":"Surendra","year":"2018","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0395","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0400","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0405","article-title":"Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment","author":"Eletreby","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0410","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/MEG.0000000000001426","article-title":"German Hepatitis C-Registry (Deutsches Hepatitis C-Register)","volume":"31","author":"Wiegand","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0415","first-page":"e5702","article-title":"Treatment outcomes for patients undergoing hemodialysis with chronic hepatitis C on the sofosbuvir and daclatasvir regimen","volume":"11","author":"Butt","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0420","article-title":"Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on haemodialysis","author":"Seo","year":"2019","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0425","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/nep.13222","article-title":"Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30mL\/min","volume":"24","author":"Goel","year":"2019","journal-title":"Nephrology"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0430","doi-asserted-by":"crossref","DOI":"10.1590\/s0004-2803.202000000-08","article-title":"Combined NS5A & NS5B nucleotide inhibitor therapy for patients with chronic hepatitis C with stage 5 chronic kidney disease on haemodialysis","author":"Debnath","year":"2020","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0435","doi-asserted-by":"crossref","DOI":"10.1590\/s0004-2803.202000000-09","article-title":"treatment of renal transplant and chronic kidney disease patients: efficacy and safety of direct-acting antiviral regimens containing sofosbuvir","author":"Michels","year":"2020","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0440","article-title":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment","author":"Poutschi","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0445","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/liv.13336","article-title":"Efficacy and safety of direct-acting antivirals- based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis","volume":"37","author":"Li","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0450","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4\u20135 chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"issue":"Suppl.","key":"10.1016\/j.nefroe.2021.11.011_bib0455","doi-asserted-by":"crossref","first-page":"S819","DOI":"10.1016\/S0168-8278(16)01602-0","article-title":"Baseline creatinine clearance is a predictor of worsening renal function while on HCV treatment with sofosbuvir-ledipasvir","volume":"64","author":"Rosenblatt","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.nefroe.2021.11.011_bib0460","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S201325142100119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S201325142100119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:46:36Z","timestamp":1761853596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S201325142100119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S201325142100119X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.11.011","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir-based regimens for HCV in stage 4\u2013stage 5 chronic kidney disease. A systematic review with meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2021.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}